NCT00034216 Collection of Blood From Patients With Cancer
| NCT ID | NCT00034216 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,750 participants |
| Start Date | 2002-07-16 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,750 participants in total. It began in 2002-07-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.
Eligibility Criteria
* INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. Ability to understand and the willingness to sign a written informed consent document. INCLUSION FOR APHERESIS: Note: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference. Hemoglobin greater than or equal to 10 mg/dL and platelet count \> 75,000/mm(3) Weight greater than 25 kg HIV negative Prothrombin Time - within normal limits Partial Thromboplastin Time - within normal limits Medically indicated central line in place or adequate peripheral venous access EXCLUSION CRITERIA: None.
Contact & Investigator
Jennifer L Marte
PRINCIPAL INVESTIGATOR
National Cancer Institute (NCI)
Frequently Asked Questions
Who can join the NCT00034216 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00034216 currently recruiting?
Yes, NCT00034216 is actively recruiting participants. Contact the research team at michell.manu@nih.gov for enrollment information.
Where is the NCT00034216 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00034216 clinical trial?
NCT00034216 is sponsored by National Cancer Institute (NCI). The principal investigator is Jennifer L Marte at National Cancer Institute (NCI). The trial plans to enroll 1,750 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.